The optimization of a chronic nitric oxide synthase (NOS) inhibition model of pre-eclampsia by evaluating physiological changes

Baijnath, Sooraj; Soobryan, Nerolen; Mackraj, Irene; Gathiram, P.; Moodley, Jagidesa

doi:10.1016/j.ejogrb.2014.08.021

Cited by 33 publications

(24 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore dysregulation in podocin could cause changes in nephrin, which further damages glomerular slit diaphragm functions . Consistent with previous findings, we also observed a significant increase in urinary podocin mRNA expression levels in preeclampsia rats compared to control, indicating compromised slit diaphragm functions. Importantly, FA treatment also reduced preeclampsia‐elevated mRNA levels of both nephrin and podocin in the urine samples (Figure ), further demonstrating its beneficial effect in improving functional outcomes in preeclampsia treatments.…”

Section: Discussionsupporting

confidence: 91%

“…First of all, we have established the preeclampsia rat model according to previously published procedures . As shown in Figure , 48 female nulliparous Sprague‐Dawley rats were evenly and randomly divided into three experimental groups on GD1, namely control, preeclampsia and preeclampsia+FA (see ).…”

Section: Resultsmentioning

confidence: 99%

“…In the current study, we utilized a well‐established rat model of preeclampsia induced by L‐NAME, an inhibitor of nitric oxide (NO) . Inhibition of NOS in mice or rats by L‐NAME administration lead to symptoms including proteinuria, hypertension, reduced glomerular filtration rate and intrauterine growth restriction (IUGR), all of which resembles those of human preeclampsia patients.…”

Section: Discussionmentioning

confidence: 99%

“…Inhibition of NOS in mice or rats by L‐NAME administration lead to symptoms including proteinuria, hypertension, reduced glomerular filtration rate and intrauterine growth restriction (IUGR), all of which resembles those of human preeclampsia patients. The L‐NAME induced animal preeclampsia models have been widely used as testing platform to search for new drugs appropriate for preeclampsia, and has been employed in our current work to evaluate the efficacy of FA in alleviating preeclampsia symptoms.…”

Section: Discussionmentioning

confidence: 99%

See 3 more Smart Citations

Ferulic acid alleviates symptoms of preeclampsia in rats by upregulating vascular endothelial growth factor

Gong

Wan

Yuan

et al. 2017

Clin Exp Pharma Physio

View full text Add to dashboard Cite

Preeclampsia is a complication affecting pregnant women worldwide, which leads to maternal and fetal morbidity and mortality. In this study, we evaluated the efficacy of ferulic acid (FA) on an N -nitro-L-arginine methyl ester hydrochloride (L-NAME) induced rat model of preeclampsia. L-NAME was administered to pregnant rats to induce preeclampsia. 48 rats were divided into three experimental groups (n=16 each): control group, preeclampsia group and preeclampsia with FA treatment (preeclampsia+FA). Physiological characteristics such as urine volume, total urine protein and blood pressure were assessed. Expressions levels of urinary nephrin and podocin mRNAs were analyzed by RT-PCR. Levels of renal vascular endothelial growth factor (VEGF), renal soluble fms-like tyrosine kinase-1 (sFlt-1) and serum placenta growth factor (PlGF) were also examined. Urine volume, total urine protein and blood pressure were markedly increased in preeclampsia group rats compared to control (P<.05), which were then significantly reduced in preeclampsia+FA group (P<.05). Expressions of urinary nephrin and podocin mRNAs, levels of VEGF, sFlt-1 and PlGF were also reversed in preeclampsia+FA group compared to preeclampsia rats (P<.05). We hereby report for the first time, FA alleviates preeclampsia symptoms in a rat preeclampsia model, supporting its potential value in treating preeclampsia.

show abstract

Section: Discussionsupporting

confidence: 91%

Section: Resultsmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Ferulic acid alleviates symptoms of preeclampsia in rats by upregulating vascular endothelial growth factor

Gong

Wan

Yuan

et al. 2017

Clin Exp Pharma Physio

View full text Add to dashboard Cite

show abstract

“…Both the l ‐NAME rat and mouse preeclampsia models have been used for testing therapeutic avenues during pregnancy. Sildenafil treatment was shown to reduce hypertension, proteinuria, and fetal demise in both early‐ and late‐onset preeclampsia as well as lowering the sFlt‐1 and soluble Endoglin (sEng) plasma levels . Other reports have failed to document the positive effects, both in rat and pregnant women suffering from preeclampsia, although in both cases the treatment was given later in gestation.…”

Section: Animal Models Of Preeclampsiamentioning

confidence: 99%

Inventory of Novel Animal Models Addressing Etiology of Preeclampsia in the Development of New Therapeutic/Intervention Opportunities

Erlandsson

Nääv

Hennessy

et al. 2015

American J Rep Immunol

View full text Add to dashboard Cite

Preeclampsia is a pregnancy-related disease afflicting 3-7% of pregnancies worldwide and leads to maternal and infant morbidity and mortality. The disease is of placental origin and is commonly described as a disease of two stages. A variety of preeclampsia animal models have been proposed, but all of them have limitations in fully recapitulating the human disease. Based on the research question at hand, different or multiple models might be suitable. Multiple animal models in combination with in vitro or ex vivo studies on human placenta together offer a synergistic platform to further our understanding of the etiology of preeclampsia and potential therapeutic interventions. The described animal models of preeclampsia divide into four categories (i) spontaneous, (ii) surgically induced, (iii) pharmacologically/substance induced, and (iv) transgenic. This review aims at providing an inventory of novel models addressing etiology of the disease and or therapeutic/intervention opportunities.

show abstract

Tetramethylpyrazine reduces the consequences of nitric oxide inhibition in pregnant rats

Shen

Zhou

et al. 2019

Journal Cellular Physiology

View full text Add to dashboard Cite

Pre-eclampsia (PE) is closely associated with perinatal morbidity and mortality and we want to investigate tetramethylpyrazine (TMP)'s effects on PE. Pregnant Sprague-Dawley rats were randomly divided into five groups: normal pregnant (PC), PE, PE+TMP 20 mg/kg, PE+TMP 40 mg/kg, and PE+TMP 60 mg/kg group. The PE rat model was established via L-NAME treatment. Systolic blood pressures (SBP) and urinary protein concentration were detected via the tail-cuff method and CBB kit, respectively. mRNA levels of key genes were analyzed via quantitative PCR and protein levels of key genes were measured by ELISA or western blot. TMP decreased SBP and urinary protein concentration of PE rats. TMP inhibited L-NAME-induced decrease in pups alive ratio, pups weight, and the ratio of pups/placenta weight and reversed L-NAME induced changes in placental histology, whereas it had little effect on placental weight. Urinary nephrin and podocin expressions were enhanced and serum placental growth factor level was decreased in PE rats, whereas TMP inhibited the above phenomena. TMP suppressed L-NAME-induced sFlt-1 upregulation in serums and kidneys of PE rats, whereas it downregulated IL-6 and MCP-1 expression in PE rats' serums, placentas and kidneys. TMP also suppressed the increase in placental sFlt-1 and vascular endothelial growth factor level caused by L-NAME. In addition, TMP inhibited CHOP and GRP78 expressions and decreased the ratio of p-elF2α/elF2α in PE rats. TMP attenuated the consequences of NO inhibition in pregnant rats. K E Y W O R D SER stress, hypertension, pre-eclampsia, proteinuria, tetramethylpyrazine

show abstract

The optimization of a chronic nitric oxide synthase (NOS) inhibition model of pre-eclampsia by evaluating physiological changes

Cited by 33 publications

References 16 publications

Ferulic acid alleviates symptoms of preeclampsia in rats by upregulating vascular endothelial growth factor

Ferulic acid alleviates symptoms of preeclampsia in rats by upregulating vascular endothelial growth factor

Inventory of Novel Animal Models Addressing Etiology of Preeclampsia in the Development of New Therapeutic/Intervention Opportunities

Tetramethylpyrazine reduces the consequences of nitric oxide inhibition in pregnant rats

Contact Info

Product

Resources

About